European Commission approves Winrevair to treat PAH in adults
Winrevair (sotatercept-csrk), Merck’s injection therapy for adults with pulmonary arterial hypertension (PAH), has been approved in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval from the European Commission specifically covers Winrevair when used in combination with other PAH therapies to improve…